The MedTech Breakthrough Awards honor excellence and recognize innovation, hard work and success in a range of health and medical technology categories, attracting thousands of nominations from over 18 countries across the world.
Nearly half of all Americans will meet the criteria to be diagnosed with a mental health condition at some point during their life, 1 said
By taking into account lifestyle factors and drug-drug interactions in addition to drug-gene interactions, IDgenetix provides invaluable information that may impact a patient s response to medications, said
May is Mental Health Month, and receiving this recognition now makes it even more meaningful, as we strive to improve mental health care through personalized PGx testing, continued Maetzold. We are incredibly honored to have earned a fourth MedTech Breakthrough Award for our innovative tests designed to improve patient care.
Observed each May, Mental Health Month was founded by Mental Health America (MHA) to promote awareness, provide vital resources and education, and advocate for the mental health and well-being of all people living in
IDgenetix is
Castle has previously won three consecutive MedTech Breakthrough Awards: Best Use of Artificial Intelligence in Healthcare in 2023 for its TissueCypher Barrett s Esophagus test, Best New Technology Solution - Dermatology in 2022 for its DecisionDx-Melanoma gene expression profile (GEP) test, and Best New Technology Solution - Oncology in 2021 for its DecisionDx-SCC and DiffDx-Melanoma GEP tests.
About MedTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical & health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices,
About Mental Health America
Mental Health America (MHA) is the nation s leading national nonprofit dedicated to the promotion of mental health, well-being and illness prevention. MHA s work is informed, designed, and led by the lived experience of those most affected. Operating nationally and in communities across the country, MHA advocates for closing the mental health equity gap while increasing nationwide awareness and understanding through public education, direct services, tools and research. MHA s annual State of Mental Health in America report is among the most widely respected health reports in the nation.
About IDgenetix
IDgenetix is a pharmacogenomic (PGx) test for depression, anxiety and other mental health conditions designed to analyze a patient s genetic make-up to guide timely and evidence-based decisions on the optimal drug for each patient. IDgenetix is designed to provide important genetic information to clinicians to help guide personalized treatment plans for their patients, with the potential to help patients achieve a faster therapeutic response and improve their chances of remission by identifying appropriate medications more efficiently than the standard of care trial-and-error approach. IDgenetix provides drug-drug and drug-gene interactions and is supported by a published, peer-reviewed randomized controlled trial that observed clinical utility over the standard of care when physicians used IDgenetix prior to prescribing a medication. IDgenetix is currently reimbursed by Medicare for the following eight mental health conditions: major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, panic disorder, obsessive-compulsive personality disorder, post-traumatic stress disorder and attention deficit hyperactivity disorder.
About
Castle s current portfolio consists of tests for skin cancers, Barrett s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the safe harbor created by those sections. These forward-looking statements include, but are not limited to, statements concerning: the ability of IDgenetix to (i) improve medication management for those struggling with neuropsychiatric conditions; (ii) provide invaluable information that may impact a patient s response to medications; (iii) arm clinicians with personalized health information to help guide medication selection and management decisions to help patients potentially achieve remission from their neuropsychiatric condition faster and (iv) help facilitate a more informed approach to mental health care in patients suffering from 10 neuropsychiatric conditions. The words can, would and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results shown in this study, including with respect to the discussion of IDgenetix in this press release; actual application of our IDgenetix test may not provide the aforementioned benefits to patients and the risks set forth under the heading Risk Factors in our Annual Report on Form 10-K for the year ended
Contact:
Email: czuckero@castlebiosciences.com
Email: amarshall@castlebiosciences.com
(C) 2024 Electronic News Publishing, source